iCAD Announces Pricing of Public Offering of Common Stock

Home/Client News/iCAD Announces Pricing of Public Offering of Common Stock

iCAD Announces Pricing of Public Offering of Common Stock

NASHUA, N.H., June 13, 2019 (GLOBE NEWSWIRE) — iCAD, Inc. (“iCAD”) (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, announced today the pricing of its previously announced underwritten registered public offering of 1,636,364 shares of its common stock at a price to the public of $5.50 per share, for gross proceeds of approximately $9.0 million. In addition, iCAD has granted the underwriter a 30-day option to purchase up to 245,454 additional shares of common stock to cover over-allotments, if any. The offering is expected to close on or about June 17, 2019, subject to the satisfaction of customary closing conditions.

By | 2019-06-13T15:20:48+00:00 June 13th, 2019|Client News|Comments Off on iCAD Announces Pricing of Public Offering of Common Stock